WallStreetZen

NYSE: MRK
Merck & Co Inc Stock Forecast, Predictions & Price Target

Analyst price target for MRK

Based on 13 analysts offering 12 month price targets for Merck & Co Inc.
Min Forecast
$88.00+8.4%
Avg Forecast
$94.69+16.64%
Max Forecast
$107.00+31.81%

Should I buy or sell MRK stock?

Strong Buy
Strong Buy
10 analysts 76.92%
Buy
0 analysts 0%
Hold
3 analysts 23.08%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Forecast return on equity

Is MRK forecast to generate an efficient return?
Company
58.32%
Industry
75.15%
Market
62.3%
MRK's Return on Equity is forecast to be high in 4 years (58.32%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is MRK forecast to generate an efficient return on assets?
Company
18.96%
Industry
16.93%
Market
19.84%
MRK is forecast to generate higher Return on Assets (18.96%) than the US Drug Manufacturers - General industry average (16.93%)
Forecast

MRK earnings per share forecast

What is MRK's earnings per share in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$6.07+33.46%
Avg 2 year Forecast
$6.61+45.27%
Avg 3 year Forecast
$5.91+29.89%
MRK's earnings are forecast to grow at a rate of 11.72% per year, which is not exceptional
Forecast

MRK revenue forecast

What is MRK's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$51.6B+9.07%
Avg 2 year Forecast
$54.3B+14.59%
Avg 3 year Forecast
$53.2B+12.32%
MRK's revenue is forecast to grow at a rate of 4.63% per year, which is not exceptional
Forecast

MRK earnings growth forecast

How is MRK forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
11.72%
Industry
25.09%
Market
20.63%
MRK's earnings are forecast to grow slower (11.72% per year) than the US Drug Manufacturers - General industry average (25.09%)
Forecast
MRK's earnings are forecast to grow slower (11.72% per year) than the US market average (20.63%)
Forecast
MRK's earnings are forecast to grow faster (11.72% per year) than the risk-free savings rate (1.1%)
Forecast

MRK revenue growth forecast

How is MRK forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
4.63%
Industry
6.43%
Market
14.47%
MRK's revenues are forecast to grow slower (4.63% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
MRK's revenues are forecast to grow slower (4.63% per year) than the US market average (14.47%)
Forecast

Merck & Stock Forecast FAQ

Is Merck & Stock a good buy in 2020, according to Wall Street analysts?

The consensus among 13 Wall Street analysts covering (NYSE: MRK) stock is to Strong Buy MRK stock.

Out of 13 analysts, 10 (76.92%) are recommending MRK as a Strong Buy, 0 (0%) are recommending MRK as a Buy, 3 (23.08%) are recommending MRK as a Hold, 0 (0%) are recommending MRK as a Sell, and 0 (0%) are recommending MRK as a Strong Sell.

What is MRK's Price Target?

According to 13 Wall Street analysts that have issued a 1 year MRK price target, the average MRK price target is $94.69, with the highest MRK stock price forecast at $107.00 and the lowest MRK stock price forecast at $88.00.

On average, Wall Street analysts predict that Merck &'s share price could reach $94.69 by Jan 20, 2022. The average Merck & stock price prediction forecasts a potential upside of 16.64% from the current MRK share price of $81.18.

What is MRK's earnings growth forecast for 2021-2023?

(NYSE: MRK) Merck &'s forecast annual earnings growth rate of 11.72% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 25.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.63%.

Merck &'s earnings in 2020 is $11,518,000,000.On average, 8 Wall Street analysts forecast MRK's earnings for 2021 to be $15,358,816,398, with the lowest MRK earnings forecast at $11,811,555,797, and the highest MRK earnings forecast at $16,718,283,473. On average, 5 Wall Street analysts forecast MRK's earnings for 2022 to be $16,718,283,473, with the lowest MRK earnings forecast at $11,811,555,797, and the highest MRK earnings forecast at $19,146,354,900.

In 2023, MRK is forecast to generate $14,947,814,724 in earnings, with the lowest earnings forecast at $12,013,895,083 and the highest earnings forecast at $17,881,734,365.

What is MRK's revenue growth forecast for 2021-2023?

(NYSE: MRK) Merck &'s forecast annual revenue growth rate of 4.63% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.47%.

Merck &'s revenue in 2020 is $47,348,000,000.On average, 4 Wall Street analysts forecast MRK's revenue for 2021 to be $130,621,086,930,687, with the lowest MRK revenue forecast at $126,100,372,026,990, and the highest MRK revenue forecast at $135,016,376,769,722. On average, 4 Wall Street analysts forecast MRK's revenue for 2022 to be $137,229,025,147,267, with the lowest MRK revenue forecast at $125,849,977,161,060, and the highest MRK revenue forecast at $145,109,237,382,325.

In 2023, MRK is forecast to generate $134,512,627,825,810 in revenue, with the lowest revenue forecast at $129,345,388,319,800 and the highest revenue forecast at $139,679,867,331,820.

What is MRK's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: MRK) Merck &'s current Earnings Per Share (EPS) is $4.55. On average, analysts forecast that MRK's EPS will be $6.07 for 2021, with the lowest EPS forecast at $4.67, and the highest EPS forecast at $6.61. On average, analysts forecast that MRK's EPS will be $6.61 for 2022, with the lowest EPS forecast at $4.67, and the highest EPS forecast at $7.57. In 2023, MRK's EPS is forecast to hit $5.91 (min: $4.75, max: $7.07).

What is MRK's forecast return on equity (ROE) for 2021-2024?

(NYSE: MRK) forecast ROE is 58.32%, which is considered strong.

What is MRK's forecast return on assets (ROA) for 2021-2024?

(NYSE: MRK) forecast ROA is 18.96%, which is higher than the forecast US Drug Manufacturers - General industry average of 16.93%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics